IOL with Drug Delivery Devices and Uninterrupted PCO Barrier Edge

Abstract

An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.

1 - 23 . (canceled) 
     
     
         24 . An ophthalmic implant ( 11 ) comprising:
 an IOL assembly ( 12 ) comprising a lens ( 24 ), and a haptic ( 28 ), the IOL assembly characterized by an anterior surface and a posterior surface, and a circumferential side wall ( 24 C), wherein the posterior surface joins the circumferential side wall in a sharply angular edge ( 24 E), the sharply angular edge defining a plane (P) of the sharply angular edge; and   a drug delivery device disposed on the haptic, the drug delivery device having a posterior surface ( 33 P), and a circumferential side wall ( 33 C), wherein the drug delivery device on the haptic does not disrupt formation of a PCO barrier.   
     
     
         25 . The ophthalmic implant of  claim 24 , wherein the drug delivery device ( 30 ) is configured and disposed on the haptic ( 28 ) such that a sharply angular edge ( 33 E) of the drug delivery device ( 30 ) is anteriorly displaced from the plane (P). 
     
     
         26 . The ophthalmic implant of  claim 25 , wherein the posterior-most surface ( 30 P) of the drug delivery device ( 30 ) is anteriorly displaced from the plane (P) by 0.1 to 1 millimeters. 
     
     
         27 . The ophthalmic implant of  claim 24 , wherein the drug delivery device ( 30 ) is configured and disposed on the haptic ( 28 ) such that a sharply angular edge ( 33 E) of the drug delivery device ( 30 ) is posteriorly displaced from the plane (P). 
     
     
         28 . The ophthalmic implant of  claim 24 , wherein the drug delivery device ( 30 ) is configured and disposed on the haptic ( 28 ) such that a sharply angular edge ( 33 E) of the drug delivery device ( 30 ) is co-planar with the plane (P). 
     
     
         29 . The ophthalmic implant of  claim 24 , wherein the drug delivery device comprises a posterior panel ( 33 ) and an anterior panel ( 36 ) joined by a pair of posts ( 35 ), with an aperture ( 34 ) bounded by the posterior panel ( 33 ), anterior panel ( 36 ) and posts ( 35 ), and the haptic is disposed within the aperture to secure the drug delivery device to the haptic or the base of the haptic. 
     
     
         30 . The ophthalmic implant of  claim 29 , wherein a portion of the circumferential side wall ( 33 C) of the posterior panel ( 33 ) immediately abuts a portion of the side wall ( 24 C) of the IOL ( 24 ). 
     
     
         31 . The ophthalmic implant of  claim 29 , wherein the circumferential side wall ( 33 C) of the posterior panel ( 33 ) is radially, outwardly displaced from the side wall ( 24 C) of the IOL ( 24 ). 
     
     
         32 . The ophthalmic implant of  claim 24 , wherein the drug delivery device comprises one or more therapeutic agents. 
     
     
         33 . The ophthalmic implant of  claim 32 , wherein the one or more therapeutic agents comprises a beta blocker, an alpha agonist, a ROCK Inhibitor, an adenosine receptor agonist, a carbonic anhydrase inhibitor, an adrenergic or cholinergic receptor activating agent, a prostaglandin analogue, a steroid, an aptamer, an antibody, a complement factor, an anti-oxidant, an anti-inflammatory agent, an anti-proliferative agents, an anti-mitotic agents, an antibiotic, or any combination thereof. 
     
     
         34 . The ophthalmic implant of  claim 32 , wherein the one or more therapeutic agents comprises or consists of a prostaglandin analogue. 
     
     
         35 . An ophthalmic implant ( 11 ) comprising:
 an IOL assembly ( 12 ) comprising a lens ( 24 ), and a haptic ( 28 ), the IOL assembly characterized by an anterior surface and a posterior surface, and a circumferential side wall ( 24 C);   the haptic ( 28 ) is joined to the lens via a haptic base ( 28 B) having a shape and size configured for acceptance of a drug delivery device ( 30 ); and   the drug delivery device ( 30 ) configured for disposition on the haptic ( 28 ), the drug delivery device ( 30 ) having an aperture ( 34 ) configured to accept the haptic base ( 28 B), the aperture ( 34 ) being keyed to the shape and size of the haptic base ( 28 B) in a configuration which inhibits rotation of the drug delivery device ( 30 ) about the haptic base ( 28 B);   such that, in an assembled configuration, the drug delivery device ( 30 ) is disposed on the haptic base ( 28 B), with the haptic base ( 28 B) occupying the aperture ( 34 ).   
     
     
         36 . The ophthalmic implant of  claim 35 , wherein the drug delivery device ( 30 ) comprises a posterior panel ( 33 ) and an anterior panel ( 36 ) joined by a pair of posts ( 35 ), with an aperture ( 34 ) bounded by the posterior panel ( 33 ), anterior panel ( 36 ) and posts ( 35 ). 
     
     
         37 . The ophthalmic implant of  claim 35 , wherein the drug delivery device ( 30 ) comprises an anterior panel ( 36 ) with an anterior surface ( 36 A) and an anterior surface edge ( 36 E), and the anterior surface edge ( 36 E) lies entirely in a plane (A) which is parallel to a major plane (B) of the IOL assembly. 
     
     
         38 . The ophthalmic implant of  claim 35 , wherein the anterior surface ( 36 A) is planar. 
     
     
         39 . The ophthalmic implant of  claim 35 , wherein an anterior panel ( 36 ) is characterized by a circumferential dimension ( 40 ) and a radial dimension ( 41 ) and the circumferential dimension ( 40 ) is larger than the radial dimension ( 41 ). 
     
     
         40 . The ophthalmic implant of  claim 35 , wherein the drug delivery device comprises one or more therapeutic agents. 
     
     
         41 . The ophthalmic implant of  claim 40 , wherein the one or more therapeutic agents comprises a beta blocker, an alpha agonist, a ROCK Inhibitor, an adenosine receptor agonist, a carbonic anhydrase inhibitor, an adrenergic or cholinergic receptor activating agent, a prostaglandin analogue, a steroid, an aptamer, an antibody, a complement factor, an anti-oxidant, an anti-inflammatory agent, an anti-proliferative agents, an anti-mitotic agents, an antibiotic, or any combination thereof. 
     
     
         42 . The ophthalmic implant of  claim 40 , wherein the one or more therapeutic agents comprises or consists of a prostaglandin analogue. 
     
     
         43 . An ophthalmic implant ( 11 ) comprising:
 an IOL assembly ( 12 ) comprising a lens ( 24 ), and a haptic ( 28 ), the IOL assembly characterized by an anterior surface and a posterior surface, and a circumferential side wall ( 24 C);   the haptic ( 28 ) is joined to the lens ( 12 ) via a haptic base ( 28 B) having a shape and size configured for acceptance of a drug delivery device ( 30 ); and   the drug delivery device ( 30 ) configured for disposition on the haptic, the drug delivery device ( 30 ) having an aperture ( 34 ) configured to accept the haptic base ( 28 B), the aperture ( 34 ) being keyed to the shape and size of the haptic base ( 28 B) in a configuration which inhibits rotation of the drug delivery device ( 30 ) about the haptic base ( 28 B);   such that, in an assembled configuration, the drug delivery device ( 30 ) is disposed on the haptic base ( 28 B), with the haptic base ( 28 B) occupying the aperture ( 34 ).   
     
     
         44 . The ophthalmic implant of  claim 43 , wherein the drug delivery device ( 30 ) comprises a posterior panel ( 33 ) and an anterior panel ( 36 ) joined by a pair of posts ( 35 ), with an aperture ( 34 ) bounded by the posterior panel ( 33 ), anterior panel ( 36 ) and posts ( 35 ). 
     
     
         45 . The ophthalmic implant of  claim 43 , wherein the drug delivery device ( 30 ) comprises an anterior panel ( 36 ) with an anterior surface ( 36 A) and an anterior surface edge ( 36 E), and the anterior surface edge ( 36 E) lies entirely in a plane (A) which is parallel to a major plane (B) of the IOL assembly. 
     
     
         46 . The ophthalmic implant of  claim 43 , wherein the anterior surface ( 36 A) is planar. 
     
     
         47 . The ophthalmic implant of  claim 43 , wherein an anterior panel ( 36 ) is characterized by a circumferential dimension ( 40 ) and a radial dimension ( 41 ) and the circumferential dimension ( 40 ) is larger than the radial dimension ( 41 ). 
     
     
         48 . The ophthalmic implant of  claim 43 , wherein the drug delivery device comprises one or more therapeutic agents. 
     
     
         49 . The ophthalmic implant of  claim 48 , wherein the one or more therapeutic agents comprises a beta blocker, an alpha agonist, a ROCK Inhibitor, an adenosine receptor agonist, a carbonic anhydrase inhibitor, an adrenergic or cholinergic receptor activating agent, a prostaglandin analogue, a steroid, an aptamer, an antibody, a complement factor, an anti-oxidant, an anti-inflammatory agent, an anti-proliferative agents, an anti-mitotic agents, an antibiotic, or any combination thereof. 
     
     
         50 . The ophthalmic implant of  claim 48 , wherein the one or more therapeutic agents comprises or consists of a prostaglandin analogue. 
     
     
         51 . An ophthalmic implant ( 11 ) comprising:
 an IOL assembly ( 12 ) comprising a lens ( 24 ), and a haptic ( 28 ), the IOL assembly characterized by an anterior surface and a posterior surface, and a circumferential side wall ( 24 C);   the haptic ( 28 ) is joined to the lens via a haptic base ( 28 B) having a shape and size configured for acceptance of a drug delivery device ( 30 );   the drug delivery device ( 30 ) configured for disposition on the haptic ( 28 ), the drug delivery device ( 30 ) having an aperture ( 34 ) configured to accept the haptic base ( 28 B); and   the haptic further comprising a first retaining structure, configured to inhibit outward migration of the drug delivery device ( 30 ) from the haptic base;   wherein in an assembled configuration, the first retaining structure ( 37 ,  36 ,  39 ) obstructs the drug delivery device ( 30 ) and inhibits outward migration of the drug delivery device ( 30 ) from the haptic base ( 28 B).   
     
     
         52 . The ophthalmic implant of  claim 51 , wherein the first retaining structure comprises a detent or shoulder on the haptic, configured to inhibit with outward movement of the drug delivery device ( 30 ) along the haptic ( 28 ). 
     
     
         53 . The ophthalmic implant of  claim 51 , wherein the first retaining structure comprises a notch in the haptic base ( 28 B); and the drug delivery device ( 30 ) comprises a second retaining feature comprising a post ( 35 ) configured to occupy the notch. 
     
     
         54 . The ophthalmic implant of  claim 51 , wherein the drug delivery device ( 30 ) comprises a posterior panel ( 33 ) and an anterior panel ( 36 ) joined by a pair of posts ( 35 ), with an aperture ( 34 ) bounded by the posterior panel ( 33 ), anterior panel ( 36 ) and the posts ( 35 ); and the drug delivery device ( 30 ) is disposed over the haptic with one of the posts ( 35 ) disposed within the notch. 
     
     
         55 . The ophthalmic implant of  claim 51 , wherein the drug delivery device ( 30 ) is configured and disposed on the haptic ( 28 ) such that a sharply angular edge ( 33 E) of the drug delivery device ( 30 ) is anteriorly displaced from a plane (P). 
     
     
         56 . The ophthalmic implant of  claim 51 , wherein the drug delivery device ( 30 ) is configured and disposed on the haptic ( 28 ) such that a sharply angular edge ( 33 E) of the drug delivery device ( 30 ) is posteriorly displaced from a plane (P). 
     
     
         57 . The ophthalmic implant of  claim 51 , wherein the drug delivery device ( 30 ) is configured and disposed on the haptic ( 28 ) such that a sharply angular edge ( 33 E) of the drug delivery device ( 30 ) is co-planar with a plane (P). 
     
     
         58 . The ophthalmic implant of  claim 55 , wherein the posterior-most surface ( 30 P) of the drug delivery device ( 30 ) is anteriorly displaced from the plane (P) by 0.1 to 1 millimeters. 
     
     
         59 . The ophthalmic implant of  claim 51 , wherein the drug delivery device comprises one or more therapeutic agents. 
     
     
         60 . The ophthalmic implant of  claim 59 , wherein the one or more therapeutic agents comprises a beta blocker, an alpha agonist, a ROCK Inhibitor, an adenosine receptor agonist, a carbonic anhydrase inhibitor, an adrenergic or cholinergic receptor activating agent, a prostaglandin analogue, a steroid, an aptamer, an antibody, a complement factor, an anti-oxidant, an anti-inflammatory agent, an anti-proliferative agents, an anti-mitotic agents, an antibiotic, or any combination thereof. 
     
     
         61 . The ophthalmic implant of  claim 59 , wherein the one or more therapeutic agents comprises or consists of a prostaglandin analogue. 
     
     
         62 . A method of treating an eye disease in a patient in need thereof, the method comprising:
 implanting an ophthalmic implant into a capsular bag of the eye of the patient, the ophthalmic implant comprising:
 an IOL assembly ( 12 ) comprising a lens ( 24 ), and a haptic ( 28 ), the IOL assembly characterized by an anterior surface and a posterior surface, and a circumferential side wall ( 24 C), wherein the posterior surface joins the circumferential side wall in a sharply angular edge ( 24 E), the sharply angular edge defining a plane (P) of the sharply angular edge; and 
 a drug delivery device disposed on the haptic, the drug delivery device having a posterior surface ( 33 P), and a circumferential side wall ( 33 C), wherein the drug delivery device on the haptic does not disrupt formation of a PCO barrier. 
   
     
     
         63 . The method of  claim 62 , wherein the drug delivery device ( 30 ) is configured and disposed on the haptic ( 28 ) such that the sharply angular edge ( 33 E) of the drug delivery device ( 30 ) is anteriorly displaced from the plane (P). 
     
     
         64 . The method of  claim 63 , wherein the posterior-most surface ( 30 P) of the drug delivery device ( 30 ) is anteriorly displaced from the plane (P) by 0.1 to 1 millimeters. 
     
     
         65 . The method of  claim 63 , further comprising allowing the capsular bag to approximate the IOL. 
     
     
         66 . The method of  claim 63 , further comprising forming a PCO barrier between the posterior portion of the capsular bag and the sharply angular edge. 
     
     
         67 . The method of  claim 63 , wherein the eye disease comprises glaucoma, wet macular degeneration, dry macular degeneration, uveitis, an infection or inflammation of the eye, or any combination thereof. 
     
     
         68 . The method of  claim 63 , wherein the implanting comprises:
 folding or rolling the ophthalmic implant into a small diameter configuration into an injector;   inserting the injector through a small slit between the cornea and sclera of the eye; and   pushing the ophthalmic implant from the injector into a tissue of the eye.